Zazove Associates’s Japer Therapeutics Warrants JSPRW Stock Holding History

Zazove Associates’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-65,456	Closed	-$6.21K	–	180
2025 Q2	$6.21K	Hold	65,456	–	–	﹤0.01%	160
2025 Q1	$7.74K	Hold	65,456	–	–	﹤0.01%	146
2024 Q4	$12.4K	Hold	65,456	–	–	﹤0.01%	127
2024 Q3	$12.4K	Hold	65,456	–	–	﹤0.01%	123
2024 Q2	$12.8K	Buy	+65,456	New	+$11.9K	﹤0.01%	124
2024 Q1	–	Sell	-65,456	Closed	-$5K	–	130
2023 Q4	$5K	Hold	65,456	–	–	﹤0.01%	129
2023 Q3	$4K	Hold	65,456	–	–	﹤0.01%	146
2023 Q2	$9K	Hold	65,456	–	–	﹤0.01%	134
2023 Q1	$12K	Hold	65,456	–	–	﹤0.01%	140
2022 Q4	$2K	Hold	65,456	–	–	﹤0.01%	148
2022 Q3	$5K	Hold	65,456	–	–	﹤0.01%	166
2022 Q2	$7K	Hold	65,456	–	–	﹤0.01%	175
2022 Q1	$22K	Buy	+65,456	New	+$36.5K	﹤0.01%	163
2021 Q3	$178K	Buy	+124,993	New	+$134K	0.02%	142

Other funds holding JSPRW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Zazove Associates's JSPRW Position: Q3 2025 in Review

Zazove Associates sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2025, closing a stake of 65,456 shares — an estimated $6.21K sold.

Zazove Associates first reported a position in JSPRW in Q3 2021 and held it in 14 quarters. The position peaked at $178K in Q3 2021. 8 funds tracked by Wall St. Rank hold JSPRW as of Q3 2025.

Zazove Associates reported no remaining Japer Therapeutics Warrants position as of Q3 2025 after selling out during the quarter.
Zazove Associates sold 65,456 Japer Therapeutics Warrants shares in Q3 2025, an estimated $6.21K.
Zazove Associates first reported a position in Japer Therapeutics Warrants in Q3 2021 and held it in 14 quarters.
Zazove Associates's Japer Therapeutics Warrants position peaked at $178K in Q3 2021.
8 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2025.

Based on Zazove Associates's 13F filing for Q3 2025, filed 17 Oct 2025.